USFDA approves emergency use of an investigational vaccine, Remdesivir

The United States Food and Drug Regulatory body recently allowed emergency use of anti-viral investigational vaccine Remdesivir to treat COVID-19 patients.

Highlights

The USFDA has approved the vaccine after an Indian-American physician, Aruna Subramaninan’s report on Remdesivir. According to the report, the vaccine shortened the recovery times of people that have fallen ill due to COVID-19 virus. The FDA has provided emergency use authorization of the drug.

Remdesivir

Remdesivir was developed to treat Ebola virus and Marburg virus. However, it was found to be ineffective in treating these diseases.

International Nonproprietary Name

Remdesivir is an International Nonproprietary Name (INN). The INN is provided to a pharmaceutical drug or active ingredient. The INN is issued in Latin, English, Russian, French, Spanish, Chinese and Arabic.

Emergency Use Authorization

The Emergency Use Authorization in the United States to approve drugs during emergency. Earlier, the US FDA had approved use of diagnostic and therapeutic tools to identify and respond 2009 swine flu outbreak.

In 2013, the FDA issued Emergency Authorization Use of CDC Human Influenza virus.

Remdesivir trial by WHO

WHO had launched 4 mega trials to treat COVID-19. It includes Remdesivir, HCQ (Hydroxychloroquine), combination of Lopinavir and Ritonavir and Interferon-beta along with the combination of Lopinavir and Ritonavir.

Month: Current Affairs - May, 2020